[1] Boullata J I, Hudson L M. Drug-nutrient interactions: a broad view with implications for practice[J]. J Acad Nutr Diet,2012,112(4): 506-517.
[2] MacDonald L, Foster B C, Akhtar H. Food and therapeutic product interactions-a therapeutic perspective[J]. J Pharm Pharm Sci,2009,12(3): 367-377.
[3] Kuhlmann J. Drug interactions in the treatment of infectious diseases[J]. Med Monatsschr Pharm,1979,2(6): 168-179.
[4] 魏少阳, 朱胤龙, 粱馨月,等. 朱砂在不同消化液中溶出汞的含量测定及影响因素分析[J]. 中国医院药学杂志,2012,32(07) 494-496.
[5] 高鹏, 刘琳, 王菲,等. 膳食钙吸收的机制及影响因素[J]. 医学综述,2010,16(11): 1666-1668.
[6] Kiang T K, Wilby K J, Ensom M H. Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions[J]. Clinical pharmacokinetics,2013,52(7): 487-510.
[7] Choi E, Zmarlicka M, Ehret M J. Vilazodone: a novel antidepressant[J]. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists,2012,69(18): 1551-1557.
[8] Siew A, Le H, Thiovolet M, et al. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles[J]. Molecular pharmaceutics, 2012,9(1): 14-28.
[9] Mendes G D, Borges A, de Cassia Val L, et al. Comparative bioavailability of cefuroxime axetil suspension formulations admin-istered with food in healthy subjects[J]. Arzneimittel-Forschung,2010,60(2): 101-105.
[10] 辛栋轶,辛学俊.双硫仑反应810例文献分析[J].医药导报,2013,32(7): 969-970.
[11] Beall D P, Henslee H B, Webb H R,et al. Milk-alkali syndrome: a historical review and description of the modern version of the syndrome[J]. The American journal of the medical sciences,2006,331(5): 233-242.
[12] Stahl S M, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants[J]. CNS spectrums, 2008,13(10): 855-870.
[13] FDA. Food-Effect Bioavailability and Fed Bioequivalence Studies. Guidance for Industry[Z].2002：1-4.
[14] CFDA. 化学药物临床药代动力学研究技术指导原则[Z]. 2005：1-2. |
